Skip to main content

Table 2 Treatment and prognosis of the patients with adult-onset Still’s disease (AOSD) during follow-up

From: Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still’s disease

  AOSD patients(N = 132)   AOSD patients(N = 132)
Medication   Prognosis  
NSAIDs 109 (83%) Relapse 35 (27%)
Corticosteroid 126 (95%) MAS 17 (13%)
DMARD 88 (67%) ICU 11 (8%)
HCQ 41 (31%) Death 4 (3%)
Azathioprine 18 (14%) Treatment step  
Sulfasalazine 11 (8%) 1 1 (1%)
Leflunomide 7 (5%) 2 27 (20%)
Methotrexate 69 (52%) 3 70 (53%)
IVIG 25 (19%) 4 34 (26%)
TNF inhibitor 8 (6%)   
IL-6 blockade 4 (3%)   
  1. AOSD adult-onset Still’s disease, NSAIDs nonsteroidal anti-inflammatory drugs, DMARD disease modifying antirheumatic drugs, HCQ hydroxychloroquine, IVIG intravenous immunoglobulin, TNF tumor necrosis factor, IL-6 interleukin-6, MAS macrophage activation syndrome, ICU intensive unit care. Values are expressed as n (%)